Logo-npj
Submitted: 15 Sep 2022
Accepted: 12 Nov 2022
ePublished: 22 Nov 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2023;12(1): e10569.
doi: 10.34172/npj.2022.10569
  Abstract View: 4949
  PDF Download: 1284

Clinical Trial

Effect of niacin on phosphorus, calcium, parathormone and vitamin D levels in hemodialysis patients; a double-blinded randomized clinical trial

Ali Mohamadi Najafabadi 1 ORCID logo, Ali Ahmadi 2, Saeed Mardani 1* ORCID logo

1 Department of Nephrology, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 School of Health, Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran
*Corresponding Author: Corresponding author: Saeed Mardani, Email: , Email: Dr.s.mardani72@gmail.com

Abstract

Introduction: Electrolyte abnormalities are one of the most common problems in hemodialysis patients. Objectives: The present study was conducted to investigate the effect of niacin on the levels of sodium, phosphorus, calcium, intact parathormone (iPTH), alkaline phosphatase (ALP) and vitamin D in hemodialysis patients.

Patients and Methods: In the present double-blinded randomized clinical trial, hemodialysis patients with phosphorus of more than 4.5 mg/dL were included in the study and were treated with niacin. The dose of niacin was increased from 50 mg to 100 mg/d in two stages on a monthly basis. Tests related to the levels of phosphorus, sodium, vitamin D, and calcium were determined before and after the intervention, and the side effects of the treatment were recorded accordingly. Data were analyzed through SPSS version 16.

Results: After the intervention, the serum levels of calcium, vitamin D, and sodium increased significantly (P<0.05), while the serum levels of iPTH and phosphate decreased significantly (P<0.05). However, the serum level of ALP did not change significantly (P>0.05). There was no significant difference in the serum levels of calcium, phosphate, vitamin D, sodium, iPTH, and ALP during the intervention in the both men and women (P>0.05). Side effects were not reported in any of the patients.

Conclusion: Niacin can increase vitamin D, sodium and calcium and decreased serum levels of phosphate and iPTH in hemodialysis patients. Therefore, it can be administered as an effective and safe supplement in the hemodialysis patients.

Trial Registration: This trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20190702044076N2; https://en.irct.ir/trial/66567, ethical code #IR.SKUMS. REC.1400.079).


Implication for health policy/practice/research/medical education: In a double-blinded randomized clinical trial in a group of hemodialysis patients, who treated niacin for the treatment of hyperphosphatemia, we found following two months of this treatment, serum vitamin D and calcium increased significantly, since serum levels of phosphate and intact parathormone were decreased.

Please cite this paper as: Mohamadi Najafabadi A, Ahmadi A, Mardani S. Effect of niacin on phosphorus, calcium, parathormone and vitamin D levels in hemodialysis patients; a double-blinded randomized clinical trial. J Nephropharmacol. 2023;12(1):e10569. DOI: 10.34172/npj.2022.10569.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 4950

Your browser does not support the canvas element.


PDF Download: 1284

Your browser does not support the canvas element.